文献速递主动脉疾病

单侧入路血管内支架的早期结局

Early outcomes with a single-sided access endovascular stent.
PubMed 文献 · J Vasc Surg · 2018-03-27

报告新型Horizon覆膜支架(Endospan,Herzliya,以色列)在两项前瞻性连续试验中的1年随访结果。该14F单入路系统由三个模块组成。FIM研究10例、关键研究30例。两项研究中39/40例成功输送并释放支架,随访期间未登记主要不良事件,主要安全性和性能终点均达到。

要点

  • Horizon支架为14F单入路系统,由三个独立引入的模块组成。
  • FIM研究10例、关键研究30例,共40例中39例成功输送并释放支架。
  • 随访期间未登记主要不良事件,两项研究的主要安全性和性能终点均达到。

核心结论

  • 两项研究结果表明,40例手术中39例成功输送并释放Horizon覆膜支架,随访期间未登记主要不良事件,两项研究的主要安全性和性能终点均达到。

研究设计与样本

  • 分析首次人体(FIM)临床研究(入组10例)和关键研究(30例)的数据,两项均为前瞻性连续试验。
  • Horizon腹主动脉瘤覆膜支架系统为14F系统,仅需单侧入路,由三个分别引入的模块组成:基底分支(髂至髂分支)、远端主动脉分支和近端主动脉分支(带裸上肾冠和主动固定)。

主要发现

  • FIM研究中,围手术期登记1例中转开放手术且失血量>1000 mL。
  • 关键研究中,围手术期未登记主要不良事件。
  • 总体1年随访中,登记2例死亡和1例与内漏无关的动脉瘤增长。
  • 两项研究中40例手术有39例成功输送并释放支架。
  • 随访期间未登记主要不良事件。

关键数值与推荐

  • 主要不良事件包括全因死亡、心肌梗死、肾衰竭、呼吸衰竭、截瘫、卒中、肠缺血和手术失血量≥1000 mL。
  • 性能终点包括装置成功输送和释放、免于动脉瘤增长≥5 mm、I型或III型内漏、支架移植物闭塞、中转开放手术、破裂和支架移植物迁移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to report the 1-year follow-up study results of the new Horizon stent graft (Endospan, Herzliya, Israel) from two different prospective consecutive trials. The Horizon abdominal aortic aneurysm stent graft system is a 14F profile system requiring only a single access site. It consists of three modules, introduced separately: base limb (iliac to iliac limb); distal aortic limb; and proximal aortic limb with a bare suprarenal crown and active fixation. METHODS: Data from the first in man (FIM) clinical study with 10 patients enrolled and the pivotal study with 30 patients were analyzed. Outcomes measured were freedom from major adverse events (MAEs) including all-cause mortality, myocardial infarction, renal failure, respiratory failure, paraplegia, stroke, bowel ischemia, and procedural blood loss ≥1000 mL. Performance end points included successful delivery and deployment of the device, freedom from aneurysm growth ≥5 mm, type I or type III endoleak, stent graft occlusion, conversion to open surgery, rupture, and stent graft migration. RESULTS: In the FIM study, one conversion to open surgery with >1000 mL of blood loss was registered perioperatively. In the pivotal study, no perioperative MAE was registered. Overall, at 1-year follow-up, two deaths and one aneurysm growth unrelated to endoleak were registered. CONCLUSIONS: The results of both the FIM and pivotal studies demonstrated that 39 of 40 procedures were successful for delivery and deployment of the Horizon stent graft. No MAE was registered during the follow-up. The primary safety and performance end points were met in both studies.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hofmann M, Pecoraro F, Planer D, et al. Early outcomes with a single-sided access endovascular stent. J Vasc Surg. 2018. PMID: 29602473. doi:10.1016/j.jvs.2017.11.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。